NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements
NLS Pharmaceutics (Nasdaq: NLSP) announced it has regained full compliance with Nasdaq listing requirements. The company received notice from Nasdaq confirming compliance with both the bid price requirement (Rule 5550(a)(2)) and equity requirement (Rule 5550(b)(1)). The compliance was achieved through balance sheet improvements, including capital raising and implementation of a reverse share split.
NLS Pharmaceutics (Nasdaq: NLSP) ha annunciato di aver riacquistato la piena conformità ai requisiti di quotazione del Nasdaq. L'azienda ha ricevuto notifica dal Nasdaq che conferma la conformità sia ai requisiti di prezzo dell'offerta (Regola 5550(a)(2)) sia ai requisiti di capitale (Regola 5550(b)(1)). La conformità è stata raggiunta grazie a miglioramenti del bilancio, inclusi raccolta di capitali e l'implementazione di un raggruppamento azionario inverso.
NLS Pharmaceutics (Nasdaq: NLSP) anunció que ha recuperado la plena conformidad con los requisitos de cotización de Nasdaq. La compañía recibió una notificación de Nasdaq confirmando la conformidad tanto con el requisito de precio de oferta (Regla 5550(a)(2)) como con el requisito de capital (Regla 5550(b)(1)). La conformidad se logró a través de mejoras en el balance, que incluyen la captación de capital y la implementación de un división inversa de acciones.
NLS Pharmaceutics (Nasdaq: NLSP)는 Nasdaq 상장 요구 사항을 완전히 준수하게 되었음을 발표했습니다. 회사는 제안 가격 요구 사항(규칙 5550(a)(2)) 및 자본 요구 사항(규칙 5550(b)(1))을 모두 준수한다는 Nasdaq의 통지를 받았습니다. 이러한 준수는 자본 조달 및 주식 병합의 이행을 포함하여 재무제표 개선을 통해 달성되었습니다.
NLS Pharmaceutics (Nasdaq: NLSP) a annoncé qu'elle avait retrouvé pleine conformité avec les exigences de cotation du Nasdaq. La société a reçu un avis de Nasdaq confirmant la conformité tant avec l'exigence de prix d'offre (Règle 5550(a)(2)) qu'avec l'exigence de capital (Règle 5550(b)(1)). La conformité a été atteinte grâce à des améliorations de bilan, y compris la levée de fonds et la mise en œuvre d'un rachat d'actions inversé.
NLS Pharmaceutics (Nasdaq: NLSP) gab bekannt, dass es die volle Konformität mit den Zulassungsanforderungen der Nasdaq wiedererlangt hat. Das Unternehmen erhielt eine Mitteilung von Nasdaq, die die Einhaltung sowohl der AngebotsPreis-anforderung (Regel 5550(a)(2)) als auch der Eigenkapitalanforderung (Regel 5550(b)(1)) bestätigt. Die Konformität wurde durch Verbesserungen der Bilanz erreicht, einschließlich Kapitalaufnahme und der Umsetzung eines Aktienzusammenlegungs.
- Regained full Nasdaq listing compliance, eliminating delisting risk
- Successfully raised new capital improving balance sheet
- Implemented reverse share split, typically indicating previous share price weakness
Insights
The regaining of Nasdaq compliance is a critical milestone for NLS Pharmaceutics, removing a significant overhang that threatened the company's listing status. The compliance was achieved through two key actions: capital raising and a reverse share split. While maintaining Nasdaq listing is essential for investor accessibility and market credibility, this news primarily addresses past concerns rather than creating new value.
The micro-cap status (
ZURICH, SWITZERLAND / ACCESSWIRE / October 28, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it has received notice from the Nasdaq Stock Market LLC ("NASDAQ") informing the Company that it has regained full compliance with the bid price requirement in Listing Rule 5550(a)(2) and the equity requirement in Listing Rule 5550(b)(1).
"We are pleased to report that Nasdaq has recognized our full compliance with their listing requirements," said Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics. "Their confirmation follows our successful efforts to improve our balance sheet, including raising new capital and implementing a reverse share split."
About NLS Pharmaceutics Ltd.
NLS is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit www.nlspharma.com.
Contact:
Investor Relations Contact
InvestorRelations@nls-pharma.com
www.nlspharma.com
SOURCE: NLS Pharmaceutics AG
View the original press release on accesswire.com
FAQ
What Nasdaq compliance requirements did NLSP meet in October 2024?
How did NLSP regain Nasdaq compliance in 2024?
What was the impact of NLSP regaining Nasdaq compliance?
